23.54
price down icon3.82%   -0.9494
 
loading
전일 마감가:
$24.49
열려 있는:
$24.53
하루 거래량:
228.91K
Relative Volume:
0.25
시가총액:
$2.03B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-5.2196
EPS:
-4.51
순현금흐름:
$-153.40M
1주 성능:
-10.48%
1개월 성능:
+1.74%
6개월 성능:
-5.02%
1년 성능:
-15.73%
1일 변동 폭
Value
$23.33
$24.71
1주일 범위
Value
$23.33
$26.44
52주 변동 폭
Value
$20.84
$49.50

빔 테라퓨틱스 Stock (BEAM) Company Profile

Name
명칭
Beam Therapeutics Inc
Name
전화
857-327-8775
Name
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
직원
374
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
BEAM's Discussions on Twitter

BEAM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BEAM 23.52 2.03B 352.57M -143.01M -153.40M -4.51
VRTX 447.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.58 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.33 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.59 24.49B 3.30B -501.07M 1.03B 11.54

빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-01-29 업그레이드 JP Morgan Neutral → Overweight
2023-12-15 다운그레이드 BofA Securities Buy → Neutral
2023-12-08 다운그레이드 Jefferies Buy → Hold
2023-10-20 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-10-20 다운그레이드 Leerink Partners Outperform → Market Perform
2023-03-21 개시 Bernstein Mkt Perform
2023-02-01 개시 Cantor Fitzgerald Overweight
2022-12-20 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-12-13 개시 Citigroup Buy
2022-06-17 개시 BMO Capital Markets Market Perform
2022-04-28 개시 Credit Suisse Neutral
2022-01-05 개시 Guggenheim Buy
2021-10-19 개시 SVB Leerink Outperform
2021-09-24 재개 Stifel Buy
2021-09-10 개시 BofA Securities Buy
2021-05-11 개시 Redburn Buy
2021-05-04 개시 RBC Capital Mkts Sector Perform
2021-03-01 다운그레이드 Barclays Overweight → Equal Weight
2021-02-16 개시 Wells Fargo Overweight
2021-01-29 다운그레이드 JP Morgan Overweight → Neutral
2021-01-06 개시 Stifel Hold
2020-08-05 개시 William Blair Outperform
2020-03-02 개시 Barclays Overweight
2020-03-02 개시 JP Morgan Overweight
2020-03-02 개시 Jefferies Buy
2020-03-02 개시 Wedbush Outperform
모두보기

빔 테라퓨틱스 주식(BEAM)의 최신 뉴스

pulisher
Nov 19, 2024

Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR

Nov 19, 2024
pulisher
Nov 16, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™

Nov 11, 2024
pulisher
Nov 10, 2024

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 09, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Beam Therapeutics president sells $1.35 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 08, 2024

Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN

Nov 07, 2024
pulisher
Nov 06, 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Beam points to positive data with key base editing asset - pharmaphorum

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 05, 2024

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s early base editing clinical data overshadowed by patient death - The Business Journals

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics to Present Data Across Hematology - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Posts Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Nov 05, 2024

빔 테라퓨틱스 (BEAM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

빔 테라퓨틱스 주식 (BEAM) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Ciaramella Giuseppe
President
Oct 14 '24
Option Exercise
2.00
41,754
83,594
211,370
Ciaramella Giuseppe
President
Oct 14 '24
Sale
26.27
51,110
1,342,752
160,260
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):